文章詳目資料

Acta Cardiologica Sinica MEDLINESCIEScopus

  • 加入收藏
  • 下載文章
篇名 Efficacy and Safety of Renal Denervation for Patients with Uncontrolled Hypertension in Taiwan: 3-Year Results From the Global SYMPLICITY Registry-Taiwan (GSR-Taiwan)
卷期 35:6
作者 Chih-Kuo LeeTzung-Dau WangYing-Hsiang LeeMartin FahyCheng-Han LeeShih-Hsien SungHsien-Li KaoYen-Wen WuTsung-Hsien Lin
頁次 618-626
關鍵字 Blood pressureCatheter ablationHypertensionNerveRenal arteryMEDLINEScopusSCIE
出刊日期 201911
DOI 10.6515/ACS.201911_35(6).20190826A

中文摘要

英文摘要

Background: It is unclear whether renal denervation (RDN) can safely result in blood pressure (BP) reductions in Asian hypertensive patients and whether such reductions would be sustainable. The study is to assess the safety and efficacy of RDN achieved by either main renal artery ablation using the Symplicity FlexTM catheter or main plus branch renal artery ablations using the Symplicity SpyralTM catheter in Taiwanese uncontrolled hypertensive patients enrolled in the Global SYMPLICITY Registry (GSR) with 3 years of follow-up. Methods: The GSR is a prospective, open-label, and all-comer registry to evaluate the safety and effectiveness of RDN in patients with uncontrolled hypertension worldwide. Results: Among 26 patients enrolled (mean age, 59.1 ±13.8 years), 8 were treated with the Symplicity FlexTM catheter, and 18 were treated with the Symplicity SpyralTM catheter. Baseline office systolic BP was 168.2 ±19.8 mmHg and diastolic BP was 89.0 ±14.3 mmHg. Office BP reductions following RDN were sustained throughout the follow-up periods of up to 3 years in the Symplicity FlexTM group and 2 years in the Symplicity SpyralTM group. In the Symplicity FlexTM group, the office systolic BP reductions were 14.9 ±14.7 mmHg and 29.7 ±25.9 mmHg at 3 months and 3 years, respectively (both p < 0.05 from baseline). In the Symplicity SpyralTM group, the office systolic BP reductions were 21.2 ±28.7 mmHg and 42.4 ±10.7 mmHg at 3 months and 2 years, respectively (both p < 0.05 from baseline). There were no significant changes in heart rate or antihypertensive medication classes. Three protocol-defined adverse events occurred in 2 patients, including new-onset end-stage renal disease, stroke, and hospitalization for new-onset heart failure. Conclusions: Given the susceptibility of Asian populations to hypertension, RDN, as a safe antihypertensive procedure with long-lasting BP-lowering effects, could reliably serve as an alternative or complementary BP-lowering strategy for patients with uncontrolled hypertension in Taiwan and other Asian countries.

本卷期文章目次

相關文獻